Imagine making medicine by grinding ingredients together like a mortar and pestle instead of dissolving them in harsh chemicals. This method uses mechanical force to trigger reactions, removing the need for toxic liquids. It's like switching from a chemical bath to a high-tech blender to create cleaner drugs.
Pharmaceutical production relies on organic solvents that cause high CO2 emissions and toxic pollution. This makes EU-based manufacturing expensive and risky due to strict environmental regulations.
A set of solvent-free mechanochemical processes using ball milling and extrusion to synthesize 6 specific APIs.
If you are an API manufacturer dealing with high solvent costs and strict EU pollution laws — this project developed mechanochemical processes that can reduce production costs by 12%. This allows for cleaner, cheaper synthesis of anticancer and antidiabetic drugs.
If you are a consultancy dealing with corporate CO2 targets — this project developed a method to reduce terrestrial ecotoxicity and CO2 emissions by more than 85%. You can implement these mechanical processes to help pharma clients meet Green Deal regulations.
If you are a chemical producer dealing with the high energy costs of organic solvents — this project developed a solvent-free approach using twin-screw extrusion and ball milling. This reduces the energy used in the synthesis of key pharmaceutical intermediates.
Based on available project data, switching to mechanochemistry can reduce production costs by 12%.
The project aims to provide proof-of-concept at a small pilot scale for 6 APIs from 3 different compound families.
Based on available project data, specific licensing terms are not listed, but the project involves 6 industry partners and 2 SMEs to validate the technology.
It addresses the European Green Deal by reducing CO2 emissions and pollution, potentially allowing manufacturers to move production back to Europe.
The project runs from 2022-10-01 to 2026-09-30, with pilot-scale validation as a primary goal.
The project features a strong industrial presence with 6 companies (including 2 SMEs), representing a 30% industry ratio. This balance between 10 universities and 4 research centers across 12 countries suggests a high capacity for translating academic mechanochemistry into practical industrial applications.
Contact Universite de Montpellier
Contact us to connect with the IMPACTIVE consortium for pilot implementation.
